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Patients with rheumatoid arthritis (RA) are at increased 
risk of developing leg ulcers. A history of leg ulcer has 
been reported by 9% of RA patients (1), compared with 
only 1% of the total adult population in UK (2) . The 
aetiology of leg ulcers in patients with RA appears to 
be multifactorial; venous insufficiency, vasculitis, and 
arterial disease are often contributory factors, either 
alone or together (3). Venous disease seems to be the 
most important factor and plays a role in up to 78% of 
cases (4). 
In patients with RA, the mean duration of chronic leg 
ulcers is from 5 to 15 months, which means that they 
are often long-lasting and resistant to treatment (5). 
The treatment commonly used is similar to that used 
for other chronic leg ulcers, i.e. compression therapy, 
if there are indications of venous disease, and different 
dressings. Other treatments commonly used include 
antibiotics, immunosuppressive therapy, skin grafting, 
and other surgical options (2). However, the slow heal-
ing tendency and high morbidity create a need for new, 
efficient, and cost-effective treatments.
Tacrolimus ointment (0.1% and 0.03%) is approved 
for treatment of atopic dermatitis. Apart from one case 
report (6), there are, to our knowledge, no other reports 
on the efficacy of topical tacrolimus in the treatment of 
leg ulcers in patients with RA. As the management of 
chronic leg ulcers in patients with RA is unsatisfactory, 
we treated leg ulcers that were unresponsive to standard 
therapy with tacrolimus ointment and report here the 
results of five patients.
CASE REPORTS
Five patients, referred to our dermatological department for 
management of refractory rheumatic leg ulcers, were treated 
with topical tacrolimus. All patients fulfilled the revised Ame-
rican College of Rheumatology criteria for RA (7). No other 
ulcer aetiology than RA and venous insufficiency was found. 
We describe here two of the successfully treated patients in 
detail and present all patients in Table I. 
Patient 1 was a 84-year-old woman, who had had seropositive 
RA for 24 years. Her medication consisted of prednisone 5 
mg/2.5 mg on alternate days. Her 3 months previously opened 
leg ulcer was initially treated with intensive local wound care 
and periodic debridement of necrotic tissue. A skin graft opera-
tion was performed, which was not successful. After 8 months 
of unsuccessful treatment, treatment with 0.1% tacrolimus 
ointment was started. It was applied into, and around, the ulcer 
every other day and covered with dressings (Unitulle®, Roussel 
Uxbridge, England and Ete®, Mölnlycke Healthcare, Göteborg, 
Sweden). After 6 weeks the ulcer was clearly healing, and after 
16 weeks it was completely healed. During treatment, no local 
adverse events occurred, but the patient had one episode of 
cystitis and one episode of acute bronchitis, which were thought 
not to be related to tacrolimus treatment.
Patient 2 was a 69-year-old woman who had had RA for 49 
year s. She was referred to our clinic because of several leg ul-
cers on each leg that had been treated at the primary healthcare 
level for 4 months. Her anti-rheumatic treatment was predniso-
lone 5 mg twice daily. Due to the large number (n = 16) and total 
area (18.8 cm2) of the ulcers, tacrolimus ointment therapy was 
started at the first consultation. After one week of treatment, 
the ulcer area was only half of the area at baseline. The ulcer 
was completely healed after 13 weeks of treatment.
Whole-blood tacrolimus concentration
The whole-blood tacrolimus concentration during treatment was 
measured in 2 patients. Patient 4, with the largest ulcer area, 
show ed the highest through-blood level of 1.7 ng/ml. Four months 
later the through-blood level was below the limit of detection 
(< 1.5 ng/ml), as was the case for patient 3. These levels indicate 
that systemic exposure is low even when tacrolimus ointment is 
applied into a leg ulcer. Serum creatinine levels showed no signs 
of elevation with a mean value before treatment of 95 (SD ± 29, 
n = 5), and after treatment of 84 (SD ± 31, n = 5). No local ad-
verse events that clearly related to tacrolimus ointment therapy 
were recorded. Interestingly, no burning or itch was reported, 
although this is the most common adverse event when treating 
atopic dermatitis (8). 
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Table I. Demographics of rheumatoid arthritis (RA) and ulcer healing in five patients treated with tacrolimus ointment
Patient number
1 2 3 4 5
Sex/age, years F/84 F/69 F/69 F/74 F/55
Duration of RA, years 24 49 20 50 30
DMARDs and corticosteroids PRE PRE MPRE, HCQ PRE, MTX, HCQ PRE, MTX
Duration of ulcer, months 11 4 13 3 24
Ulcer size before tacrolimus, cm2 6.00 18.75 12.75 52.88 3.75
Ulcer size after tacrolimus, cm2 0.00 0.00 6.75 20.50 5.00
Treatment time, weeks 16 13 33 45 22
DMARDs: disease-modifying-anti-rheumatic drugs; PRE: prednisolone; MPRE: methylprednisolone; HCQ: hydroxychloroquine; MTX: methotrexate.
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DISCUSSION
Complete healing of chronic leg ulcers in RA patients 
treated with tacrolimus ointment was observed in 2 
of the 5 patients. Prior to tacrolimus treatment these 
patients (patients 1 and 2) had been treated for several 
months with standard treatments without any significant 
healing of the ulcers. Response to tacrolimus treatment 
was relatively rapid. In patients 3 and 4 healing was 
initially good, but stopped before the ulcers were com-
pletely healed. The reason for this, and for the increase 
in the ulcer area in patient 5, is not clear, but we suspect 
that bacterial infections may play a role. 
Contaminated chronic ulcers often heal poorly (2). 
The two patients with a response to tacrolimus treatment 
had no, or minor, bacterial colonization of the ulcers 
when tacrolimus therapy was initiated, and had no 
significant ulcer infections during treatment. Patients 
3, 4 and 5 had bacterial colonization of the ulcers with 
Staphylococcus aureus, and Pseudomonas spp., Entero-
coccus faecalis, or Entero coccus cloacae at the time of 
initiation of treat ment. At the time of treatment discon-
tinuation these patients had clinically evident infections 
with either S. aureus or Pseudomonas spp. Bacterial 
colonization of the ulcer at treatment initiation seemed 
to predict a less favourable outcome, and thus thorough 
clearing of the ulcer base and antimicrobic treatment 
should be considered before starting treatment with 
tacrolimus, even in the absence of clinical infection.
The main mechanism of action of tacrolimus is the 
suppression of early activation of T lymphocytes. Inter-
estingly, T-cell activation due to staphylococcal entero-
toxins occurs via this same pathway (8). In infected 
ulcers the suppression of T-lymphocyte activation could 
result in increased manifestation of infection.  
As the T cell is the cell type most likely to be affected 
by tacrolimus, the present study suggests a role for T 
cells in rheumatoid ulcers. Topical tacrolimus inhibits 
cytokine production, and is locally immunomodulating 
(8), which could suppress the vasculitic component 
likely to be involved in the ulcers associated with RA 
and thus promote healing. Other possible mechanisms 
include inhibition of other pro-inflammatory cells, such 
as tissue mast cells, which are a rich source of cytokines 
and serine proteases (9). TGF-β seems to be important 
for wound healing (10). Tacrolimus upregulated the re-
lease of TGF-β in keratinocytes (11). On the other hand, 
both an in vitro and in vivo study have suggested that 
tacrolimus inhibits the enhanced effects of TGF-β on 
wound healing (10). One-year treatment with tacrolimus 
ointment in patients with atopic dermatitis is associated 
with an increase in collagen synthesis (12). This may 
be a major advantage in ulcer healing compared with 
topical corticosteroids, which are widely used for the 
treatment of dermatitis surrounding ulcers. 
The patient material described here is small and un-
controlled, but nevertheless, the results are promising 
and a prospective, controlled, double-blinded study 
is warranted. Further studies should attempt to define 
the subgroup of patients that benefits from tacrolimus 
treatment and to establish the role of ulcer infections 
in the treatment response. 
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